PMID: 11921492Mar 30, 2002Paper

Beta-lactam resistance: clinical implications for pediatric patients

The Journal of International Medical Research
A S Dajani

Abstract

The emergence of resistance to established antibiotic agents such as beta-lactams has been reported worldwide and poses a serious challenge to the management of pediatric infections. The most common mechanism of resistance involves the production of an enzyme that inactivates the antibiotic before it can be effective. Streptococcus pneumoniae, the most common cause of pediatric respiratory tract infections, exhibits variable resistance to penicillins and aminopenicillin due to alterations in its penicillin-binding proteins (PBPs). Haemophilus influenzae and Moraxella catarrhalis show moderate and high beta-lactamase-mediated resistance to aminopenicillins, although they remain susceptible to beta-lactam/beta-lactamase inhibitor combinations. Methicillin-resistant Staphylococcus aureus, a frequent cause of skin and soft-tissue infections, has shown PBP-mediated beta-lactam resistance, prompting the wide-spread use of vancomycin to eradicate this pathogen. Finally, PBP-mediated resistance has been observed in a large proportion of isolates of coagulase-negative staphylococci, which account for a high proportion of nosocomial infections, particularly in neonatal intensive care units. The challenge is to control the emergence of be...Continue Reading

References

Jan 1, 1979·Reviews of Infectious Diseases·M H Richmond
Sep 1, 1992·The Journal of Antimicrobial Chemotherapy·J LiñaresR Martín
Nov 1, 1989·American Family Physician·M L Kabongo
Jul 1, 1988·The Journal of Antimicrobial Chemotherapy·A Brisson-NoëlP Courvalin
Jan 1, 1988·Clinical Microbiology Reviews·K Bush
May 1, 1988·The American Journal of Medicine·P F ViladrichR Pallares
Jun 30, 1986·The American Journal of Medicine·W E SiegenthalerR Luthy
Nov 1, 1985·Pediatric Infectious Disease·W R JarvisJ M Hughes
Dec 1, 1984·The Journal of Antimicrobial Chemotherapy·C Watanakunakorn
Mar 1, 1980·The Journal of Antimicrobial Chemotherapy·G G GrassiP Sala
Jul 1, 1995·Antimicrobial Agents and Chemotherapy·G A PankuchP C Appelbaum
May 1, 1995·The Pediatric Infectious Disease Journal·G H McCracken
Jan 18, 1995·JAMA : the Journal of the American Medical Association·L F McCaig, J M Hughes
Jun 15, 1994·JAMA : the Journal of the American Medical Association·R F BreimanR R Facklam
Jan 1, 1997·Trends in Microbiology·R E Hancock
Jul 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·A Tomasz, R Munoz
Sep 1, 1997·Pediatric Research·E I Tuomanen
Dec 16, 1998·The Pediatric Infectious Disease Journal·T Heiskanen-KosmaM Leinonen
Mar 12, 1999·Annual Review of Medicine·J Huebner, D A Goldmann
Jun 23, 1999·Mayo Clinic Proceedings·S Alvarez-Elcoro, M J Enzler
Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M B EdmondR P Wenzel
Oct 20, 1999·International Journal of Antimicrobial Agents·J D Williams
Nov 7, 1999·Drugs·A E van den Bogaard, E E Stobberingh
Dec 2, 1999·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·R N Jones
Dec 14, 1999·International Journal of Antimicrobial Agents·A PortilloC Torres
Jan 5, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·B A SissonG P Rabalais
Feb 5, 2000·The Journal of Hospital Infection·F C Tenover

❮ Previous
Next ❯

Citations

May 26, 2004·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Shigeru FujimuraAkira Watanabe
May 1, 2005·Current Therapeutic Research, Clinical and Experimental·Martin S Lipsky
Nov 29, 2011·The Journal of International Medical Research·H NazikF Tabak
Feb 11, 2004·The Pediatric Infectious Disease Journal·Antonio Arrieta, Jasjit Singh
Apr 13, 2019·Brazilian Journal of Microbiology : [publication of the Brazilian Society for Microbiology]·Alejandro Miguel Figueroa-LópezErnesto Uriel Cantú-Soto

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.